✦ LIBER ✦

Cost-effectiveness analysis of sunitinib in patients with metastatic and/or unresectable gastrointestinal stroma tumours (GIST) after progression or intolerance with imatinib

✍ Scribed by Luis Paz-Ares; Xavier García del Muro; Enrique Grande; Paloma González; Max Brosa; Silvia Díaz

Book ID: 107596451
Publisher: Springer Milan
Year: 2008
Tongue: Spanish
Weight: 461 KB
Volume: 10
Category: Article
ISSN: 1699-048X
DOI: 10.1007/s12094-008-0297-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II study of dovitinib in patients

Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib

✍ Kang, Y-K; Yoo, C; Ryoo, B-Y; Lee, J J; Tan, E; Park, I; Park, J H; Choi, Y J; J 📂 Article 📅 2013 🏛 Nature Publishing Group 🌐 English ⚖ 682 KB

7511 POSTER Safety and efficacy results

7511 POSTER Safety and efficacy results of sunitinib from a worldwide treatment- use trial of gastrointestinal stromal tumour (GIST) patients (pts) with resistance or intolerance to prior imatinib therapy

✍ Seddon, B.; Reichardt, P.; Ruka, W.; Kang, Y.K.; Baum, C.M.; Demetri, G.D. 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 64 KB

212 POSTER A phase II study of the KIT i

212 POSTER A phase II study of the KIT inhibitor XL820 in patients with advanced gastrointestinal stromal tumors (GIST) resistant to or intolerant of imatinib and/or sunitinib

✍ A.J. Wagner; S. Yazji; J.A. Morgan; E. Choy; S. George; M. Hohos; M. O'Mara; G.D 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 59 KB

Efficacy and Safety of Regorafenib in Pa

Efficacy and Safety of Regorafenib in Patients With Metastatic and/or Unresectable GI Stromal Tumor After Failure of Imatinib and Sunitinib: A Multicenter Phase II Trial

✍ George, S.; Wang, Q.; Heinrich, M. C.; Corless, C. L.; Zhu, M.; Butrynski, J. E. 📂 Article 📅 2012 🏛 American Society of Clinical Oncology 🌐 English ⚖ 248 KB

A cost-effectiveness analysis of sunitin

A cost-effectiveness analysis of sunitinib in patients with metastatic renal cell carcinoma intolerant to or experiencing disease progression on immunotherapy: perspective of the Spanish National Health System

✍ L. Paz-Ares; J. G. Del Muro; E. Grande; S. Díaz 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 170 KB